JPRN-jRCT2080223685已完成1 期
A Phase I, Open-label Single Dose Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Nemolizumab in Pediatric Patients With Atopic Dermatitis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 6age old 至 <= 12age old（—）
- 性别
- All
入选标准
- •Atopic Dermatitis with moderate or severe pruritus
排除标准
- •1. Patients with Hepatitis B virus or hepatitis C virus infection
- •2. Patients with Evidence of tuberculosis (TB) infection
- •3. Patients with moderate or severe asthema symptoms
- •4. Patients with immune deficiency
研究者
相似试验
已完成
1 期
An Open label, Single Ascending Dose Study of Intravenous and Oral Doses of BRN-002 to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy ParticipantsAtherosclerosisACTRN12621001479897Beren Therapeutics, PBC29
进行中（未招募）
1 期
Study to evaluate the safety of solriamfetol, and the way the body handles it, in children with narcolepsyarcolepsyMedDRA version: 21.1Level: LLTClassification code 10021235Term: Idiopathic narcolepsySystem Organ Class: 100000004852EUCTR2019-003008-11-NLJazz Pharmaceuticals, Inc.12
尚未招募
1 期
A Phase 1 study to evaluate safety and tolerability of ES-481 in healthy volunteersNeurological - EpilepsyEpilepsyACTRN12619001591145ES Therapeutics LLC80
已完成
1 期
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FlecIH-104 in Healthy VolunteersParoxysmal atrial fibrillationACTRN12620000461998InCarda Therapeutics Australia, Pty, Ltd12
撤回
不适用
A Phase 1, Open-Label, Single Ascending Dose Study to Evaluate the Pharmacokinetics and Safety of Solriamfetol in Pediatric Subjects with NarcolepsyExcessive daytime sleepiness10040998NL-OMON49961Jazz Pharmaceuticals5